Table 1.

Amplification and overexpression of D cyclins in human tumors

D Cyclin	Enzymes	Tumors	Incidence Rate	References
D1	CCND1 Amplification	ESCC	23–57%	[31, 32, 174]
		HNSCC	26–39%	[27, 175]
		NSCLC	5–30%	[22, 23]
		Endometrial cancer	26%	[29, 30]
		Melanoma	0–25%	[7, 28]
		Pancreatic cancer	25%	[7, 21]
		Breast cancer	15–20%	[22, 25]
		Colorectal carcinoma	2.5%	[7, 176]
	Overexpression	ESCC	42–87%	[177, 178]
		HNSCC	20–68%	[27, 175]
		NSCLC	18–76%	[24, 58, 179]
		Endometrial cancer	40–56%	[29, 30]
		Melanoma	30–65%	[7, 28]
		Pancreatic cancer	42–82%	[7, 21]
		Breast cancer	50–70%	[22, 25]
		Colorectal carcinoma	55%	[7, 180]
D2	CCND2 Amplification	Germ cell tumor	15.38%	[181]
		Adrenal carcinoma	12%	[182]
		Glioma	1.95–5%	[44, 181, 182]
		ESCC	0.58–5%	[181, 182]
		Lung SCC	1–4%	[181, 182]
		Colorectal carcinoma	0.97–3%	[181]
		Breast cancer	0.61–3%	[181, 182]
		Non-Hodgkin lymphoma	0.92%	[181]
	Overexpression	Lymphoplasmacytic lymphoma	100%	[183]
		B-cell chronic lymphocytic leukemia	85%	[183]
		Colon carcinoma	57%	[184]
		AML	47%	[183]
		Gastric cancer	26.2%	[55]
		Diffuse large B-cell lymphoma	10.6%	[185]
D3	CCND3 Amplification	Colorectal carcinoma	0.3–21%	[181, 182, 186]
		ESCC	1.78–10%	[181, 182]
		HNSCC	4%	[182]
		Gastric cancer	1.96–3%	[181, 182]
		Breast cancer	0.73–3%	[181, 182]
		Urothelial carcinoma	3%	[182]
	Overexpression	Thyroid carcinoma	72%	[187]
		Melanoma	20–42%	[188]
		B-cell chronic lymphocytic leukemia	20–41%	[189–191]
		Oral SCC	39%	[192]
		Colon carcinoma	21–35%	[184, 186]
		Breast cancer	30%	[193]
		Non-Hodgkin lymphoma	22%	[194]
		Renal cell carcinoma	16%	[195]